Agilent Technologies, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Padraig McDonnell
- Full Time Employees
- 18,100
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 5301 Stevens Creek Boulevard Santa Clara CA United States of America 95051
- IPO Date
- Nov 18, 1999
- CIK
- 0001090872
- Website
- agilent.com
- Similar Companies
- Business
- Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services, and consumables for the life sciences, diagnostics, chemical analysis, and applied markets. The company offers a broad portfolio of products and services including gas chromatography and liquid chromatography systems; mass spectrometry and molecular spectroscopy instruments; microarrays, automation, and informatics solutions; bioreagents, FISH probes, target enrichment, and next-generation sequencing tools; immunohistochemistry and pathology solutions; genomics, proteomics, and cell analysis platforms; sample preparation, GC and HPLC columns, spectrometry supplies, and consumables; as well as laboratory management services encompassing enterprise asset management, compliance support, training, and CrossLab virtual assist for remote technical support. Headquartered in Santa Clara, California, Agilent operates globally in more than 100 countries, serving analytical laboratories, pharmaceutical, biopharma, clinical diagnostics, environmental, forensics, food, energy, academia, and government sectors; it was spun off from Hewlett-Packard in 1999. Recent developments include the completion of its $925 million acquisition of BIOVECTRA, Inc., a Canada-based contract development and manufacturing organization specializing in biologics, active pharmaceutical ingredients, sterile fill-finish, plasmid DNA, mRNA, lipid nanoparticles, antibody-drug conjugates, and high-potency APIs, enhancing Agilent's CDMO capabilities for gene editing and therapeutics; a $7 million investment to modernize R&D and applications labs in Delaware; the launch of the Agilent Innovation Hub in partnership with the University of Melbourne; a strategic collaboration with SeqOne for liquid biopsy data analysis in oncology; and expansions such as a $725 million nucleic acid therapeutics facility in Frederick, Colorado, alongside new product launches driving growth in specialty CDMO services for siRNA and GLP-1 modalities.
Company News
Bank of America Corp DE Makes New Investment in Agilent Technologies, Inc. $A
CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Announces Cash Dividend of 25.5 Cents per Share
Corient Private Wealth LP Boosts Holdings in Agilent Technologies, Inc. $A
Agilent to Participate in J.P. Morgan U.S. All Stars Conference
Arizona State Retirement System Boosts Stock Position in Agilent Technologies, Inc. $A
Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors
Agilent (A) Upgraded to Buy: What Does It Mean for the Stock?
Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System
Agilent Introduces the Cary 635 FTIR Spectrometer
INTURAI VENTURES COMPLETES DOMECOMMAND ACQUISITION
International Markets and Agilent (A): A Deep Dive for Investors
Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance
Agilent Technologies, Inc. (A) Q3 2026 Earnings Call Transcript
Agilent Technologies Q3 Earnings Call Highlights
Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Agilent Technologies (A) Q3 Earnings and Revenues Top Estimates
Agilent raises annual profit forecast on improving lab tools demand
Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
Agilent Technologies (A) is a Great Momentum Stock: Should You Buy?